Orexigen Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Orexigen Therapeutics sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Orexigen Therapeutics: 17 sponsored US clinical trials, none currently recruiting.
Orexigen Therapeutics sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 7 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 3 trials.
Top-decile sponsor footprint
Orexigen Therapeutics ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants
NCT02735603
Naltrexone/Bupropion Cardiovascular Outcomes Study
NCT02638129
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
NCT02259179
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
NCT01764386
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
NCT01601704
A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
NCT00711477
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
NCT00758966
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
NCT00709371
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
NCT00624858
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
NCT00567255
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
NCT00532779
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
NCT00563563
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
NCT00474630
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
NCT00456521
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
NCT00339014
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
NCT00364871
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Therapeutic Areas
How the Orexigen Therapeutics archive is shaped
17 indexed studies, none listed as recruiting (0% open); 13 completed (76%).
Phase mix: 7 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Obesity (3 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Orexigen Therapeutics: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Orexigen Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Orexigen Therapeutics page
17 registered trials is a research-attention snapshot, not an endorsement of Orexigen Therapeutics or any single study.
- None of Orexigen Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Obesity is the condition Orexigen Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Orexigen Therapeutics pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.